**2020**

1. Cappy P, Chaillon A, Pillonel J, Essat A, Chaix ML, Meyer L, Barin F, Tiberghien P, Laperche S HIV transmission network analysis allows identifying unreported risk factors in HIV-positive blood donors in France. ***Transfusion*** Trans- 2020-0603.R2
2. Novelli S, Lécuroux C, Goujard C, Reynes J, Villemant A, Blum L, Essat A, Avettand-Fénoël V, Launay O, Molina JM, Bourgeois C, Meyer L. Persistent monocyte activation in people followed since acute and early HIV infection compared with two well-characterized groups of HIV-uninfected controls. ***EbioMedecine in press***
3. Angin M, Volant S, Passaes C, Lecuroux C, Monceaux V, Dillies MA, Valle-Casuso JC, Pancino G, Vaslin B, Le Grand R, Weiss L, Goujard C, Meyer L, Boufassa F, Müller-Trutwin M, Lambotte O, Sáez-Cirión A. [Metabolic plasticity of HIV-specific CD8+ T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection.](https://pubmed.ncbi.nlm.nih.gov/32694646/) ***Nat Metab*** 2019 Jul;1(7):704-16. doi: 10.1038/s42255-019-0081-4.
4. Azar P, Mejia JE, Cenac C, Shaiykova A, Youness A, Laffont S, Essat A, Izopet J, Passaes C, Müller-Trutwin M, Delobel P, Meyer L, Guery JC. TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women. ***JCI Insight*** 2020
5. Novelli S, Delobel P, Bouchaud O, Avettand-Fenoel V, Fialaire P, Abel S, Souala F, Raffi F, Catalan P, Weiss L, Meyer L, Goujard C. Long-term sex differences in outcomes following acute HIV-1 infection. ***JIAS*** 2020
6. Rohner E, Bütikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, Taghavi K, Moore RD, Goedert JJ, Gill MJ, Silverberg MJ, D'Souza G, Patel P, Castilho JL, Ross J, Sohn A, Bani-Sadr F, Taylor N, Paparizos V, Bonnet F, Verbon A, Vehreschild JJ, Post FA, Sabin C, Mocroft A, Dronda F, Obel N, Grabar S, Spagnuolo V, Quiros-Roldan E, Mussini C, Miro JM, Meyer L, Hasse B, Konopnicki D, Roca B, Barger D, Clifford GM, Franceschi S, Egger M, Bohlius J. [Cervical cancer risk in women living with HIV across four continents: A multicohort study.](https://pubmed.ncbi.nlm.nih.gov/31215037/) ***Int J Cancer***. 2020 Feb 1;146(3):601-609. doi: 10.1002/ijc.32260.
7. Thorball CW, Oudot-Mellakh T, Hammer C, Santoni FA, Costagliola D, Goujard C, Meyer L, Wang SS, Hussain SK, Theodorou I, Cavassini M, Kaiser L, Rauch A, Battegay M, Hoffmann M, Bernasconi E, Günthard HF, McLaren PJ, Rabkin CS, Besson C, Fellay J. Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. ***Haematologica*** 2020
8. Veil R, Poizot-Martin I, Reynes J, Goujard C, Seng R, Delobel P, Cotte L, Duvivier C, Rey D, Tran L, Surgers L, Allavena C, Lascoux-Combe C, Cheret A\*, Meyer L\*. Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection. ***AIDS*** 2020
9. Visseaux B, Assoumou L Mahjoub N, Grude M, Trabaud MA; Raymond S; Wirden M; Morand-Joubert, L; Roussel C; Montes B; Bocket L; Fafi-Kremer S, Amiel C, De Monte A; Stefic K; Pallier C, Tumiotto C, Maillard A; Vallet S; Ferre V; Bouvier M, Dina J; Signori-Schmuck A; Carles MJ, Plantier JC, Meyer L; Descamps D, Chaix ML. Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance but higher diversity, clustering and virulence? ***JAC*** 2020

**2019**

1. Avettand-Fénoël V, Mélard A, Gueudin M, Maillard A, Dina J, Gousset M, Chaix ML, Lerolle N, Viard JP, Meyer L, Plantier JC and Rouzioux C for the ANRS-AC11 HIV Quantification Working Group. Comparative performance of the Biocentric Generic Viral Load, Roche CAP/CTM v1.5, Roche CAP/CTM v2.0 and m2000 Abbott assays for quantifying HIV-1 B and non-B strains: underestimation of some CRF02 strains. ***J Clin Virol*** 2019; 110: 36–41
2. Bouvin-Pley Mélanie, Maxime Beretta, Alain Moreau, Emmanuelle Roch, Asma Essat, Cécile Goujard, Marie-Laure Chaix, Nathalie Moiré, Loïc Martin, Laurence Meyer, Francis Barin, and Martine Braibant. Evolution of the Envelope Glycoprotein of HIV-1 Clade B towards Higher Infectious Properties over the Course of the Epidemic. ***J Virol*** 2019 Mar 5;93(6). pii: e01171-18.
3. Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage Iii GR, Bonnet F, Le Marec F, Moore RD, Reiss P, van Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA. [Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals.](https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/30883859) ***Stat Med.*** 2019 Mar 18. doi: 10.1002/sim.8120.
4. Chaillon A, Delaugerre C, Mahjoub N, Brenner B, Capitant C, Carette D, Nere ML, Pialoux G, Cua E, Cotte L, Tremblay C, Spire B, Wainberg M, Davey M. Smith, Goujard C, **Meyer L**, Molina JM, and Chaix ML. In Depth Sampling of High Risk Populations to Characterize HIV Transmission Epidemics among Young MSM using PrEP in France and Quebec. ***Open Forum Infectious Diseases*** 2019
5. Coindre S, Tchitchek N, Alaoui L, Vaslin B, Bourgeois C, Goujard C, Lecuroux C, Bruhns P, Le Grand R, Beignon AS, Lambotte O, Favier B. Mass Cytometry Analysis Reveals Complex Cell-State Modifications of Blood Myeloid Cells During HIV Infection. ***Front Immunol.*** 2019 Nov 22;10:2677.
6. Delagreverie HM, Grude M, Lambert-Niclot S, Nere ML, Jadand C, Leport C, Raffi F, Ghislain M, Goujard C, Meyer L, Calvez V, Katlama C, Flandre P, Barin F, Delaugerre C. [Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants.](https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/30690509) ***J Antimicrob Chemother***. 2019 Jan 23. doi: 10.1093/jac/dkz004.
7. [Henriquez S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Henriquez%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31385864), [Lecuroux C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lecuroux%20C%5BAuthor%5D&cauthor=true&cauthor_uid=31385864), [Bitu M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bitu%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31385864), [Avettand-Fenoel V](https://www.ncbi.nlm.nih.gov/pubmed/?term=Avettand-Fenoel%20V%5BAuthor%5D&cauthor=true&cauthor_uid=31385864), [Churaqui F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Churaqui%20F%5BAuthor%5D&cauthor=true&cauthor_uid=31385864), [Catalan P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Catalan%20P%5BAuthor%5D&cauthor=true&cauthor_uid=31385864), [Cheret A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cheret%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31385864), [Boufassa F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Boufassa%20F%5BAuthor%5D&cauthor=true&cauthor_uid=31385864), [Saez-Cirion A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Saez-Cirion%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31385864), [Monceaux V](https://www.ncbi.nlm.nih.gov/pubmed/?term=Monceaux%20V%5BAuthor%5D&cauthor=true&cauthor_uid=31385864), [Meyer L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Meyer%20L%5BAuthor%5D&cauthor=true&cauthor_uid=31385864), [Goujard C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Goujard%20C%5BAuthor%5D&cauthor=true&cauthor_uid=31385864), [Lambotte O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lambotte%20O%5BAuthor%5D&cauthor=true&cauthor_uid=31385864), [Bourgeois C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bourgeois%20C%5BAuthor%5D&cauthor=true&cauthor_uid=31385864); [ANRS CO6 PRIMO, the ANRS CO21 CODEX cohorts](https://www.ncbi.nlm.nih.gov/pubmed/?term=ANRS%20CO6%20PRIMO%2C%20the%20ANRS%20CO21%20CODEX%20cohorts%5BCorporate%20Author%5D). The proportion of CD57+ cells among effector CD8+ T cells is lower HIV controllers compared to ART treated patients. [***AIDS***.](https://www.ncbi.nlm.nih.gov/pubmed/31385864?dopt=Abstract) 2019 Aug 2. doi: 10.1097/QAD.0000000000002342.
8. [Lodi S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lodi%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Phillips A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Phillips%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Lundgren J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lundgren%20J%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Logan R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Logan%20R%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Sharma S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sharma%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Cole SR](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cole%20SR%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Babiker A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Babiker%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Law M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Law%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Chu H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Chu%20H%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Byrne D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Byrne%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Horban A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Horban%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Sterne JAC](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sterne%20JAC%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Porter K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Porter%20K%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Sabin C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sabin%20C%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Costagliola D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Costagliola%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Abgrall S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Abgrall%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Gill J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gill%20J%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Touloumi G](https://www.ncbi.nlm.nih.gov/pubmed/?term=Touloumi%20G%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Pacheco AG](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pacheco%20AG%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [van Sighem A](https://www.ncbi.nlm.nih.gov/pubmed/?term=van%20Sighem%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Reiss P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Reiss%20P%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Bucher HC](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bucher%20HC%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Montoliu Giménez A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Montoliu%20Gim%C3%A9nez%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Jarrin I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Jarrin%20I%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Wittkop L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wittkop%20L%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Meyer L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Meyer%20L%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Perez-Hoyos S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Perez-Hoyos%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Justice A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Justice%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Neaton JD](https://www.ncbi.nlm.nih.gov/pubmed/?term=Neaton%20JD%5BAuthor%5D&cauthor=true&cauthor_uid=31063192), [Hernán MA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hern%C3%A1n%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=31063192); [INSIGHT START Study Group and the HIV-CAUSAL Collaboration](https://www.ncbi.nlm.nih.gov/pubmed/?term=INSIGHT%20START%20Study%20Group%20and%20the%20HIV-CAUSAL%20Collaboration%5BCorporate%20Author%5D). Effect estimates in randomized trials and observational studies: comparing apples with apples. [***Am J Epidemiol.***](https://www.ncbi.nlm.nih.gov/pubmed/31063192?dopt=Abstract) 2019 May 7. pii: kwz100. doi: 10.1093/aje/kwz100. [Epub ahead of print]
9. Paraskevis D, Beloukas A, Stasinos K, Pantazis N, de Mendoza C, Bannert N, Meyer L, Zangerle R, Gill J, Prins M, d'Arminio Montforte A, Kran AB, Porter K, Touloumi G; CASCADE collaboration of EuroCoord. [HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors.](https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/30616632) ***BMC Med.*** 2019 Jan 8;17(1):4. doi: 10.1186/s12916-018-1241-1.
10. [Rohner E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Rohner%20E%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Bütikofer L](https://www.ncbi.nlm.nih.gov/pubmed/?term=B%C3%BCtikofer%20L%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Schmidlin K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Schmidlin%20K%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Sengayi M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sengayi%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Maskew M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Maskew%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Giddy J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Giddy%20J%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Taghavi K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Taghavi%20K%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Moore RD](https://www.ncbi.nlm.nih.gov/pubmed/?term=Moore%20RD%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Goedert JJ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Goedert%20JJ%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Gill MJ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gill%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Silverberg MJ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Silverberg%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [D'Souza G](https://www.ncbi.nlm.nih.gov/pubmed/?term=D%27Souza%20G%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Patel P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Patel%20P%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Castilho JL](https://www.ncbi.nlm.nih.gov/pubmed/?term=Castilho%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Ross J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ross%20J%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Sohn A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sohn%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Bani-Sadr F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bani-Sadr%20F%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Taylor N](https://www.ncbi.nlm.nih.gov/pubmed/?term=Taylor%20N%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Paparizos V](https://www.ncbi.nlm.nih.gov/pubmed/?term=Paparizos%20V%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Bonnet F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bonnet%20F%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Verbon A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Verbon%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Vehreschild JJ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Vehreschild%20JJ%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Post FA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Post%20FA%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Sabin C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sabin%20C%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Mocroft A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mocroft%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Dronda F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dronda%20F%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Obel N](https://www.ncbi.nlm.nih.gov/pubmed/?term=Obel%20N%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Grabar S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Grabar%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Spagnuolo V](https://www.ncbi.nlm.nih.gov/pubmed/?term=Spagnuolo%20V%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Quiros-Roldan E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Quiros-Roldan%20E%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Mussini C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mussini%20C%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Miro JM](https://www.ncbi.nlm.nih.gov/pubmed/?term=Miro%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Meyer L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Meyer%20L%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Hasse B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hasse%20B%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Konopnicki D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Konopnicki%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Roca B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Roca%20B%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Barger D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Barger%20D%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Clifford GM](https://www.ncbi.nlm.nih.gov/pubmed/?term=Clifford%20GM%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Franceschi S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Franceschi%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Egger M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Egger%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31215037), [Bohlius J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bohlius%20J%5BAuthor%5D&cauthor=true&cauthor_uid=31215037). Cervical cancer risk in women living with HIV across four continents: A multicohort study. [***Int J Cancer.***](https://www.ncbi.nlm.nih.gov/pubmed/31215037?dopt=Abstract) 2019 Jun 19. doi: 10.1002/ijc.32260.
11. Stefic K, Bouvin-Pley M, Essat A, Visdeloup C, Moreau A, Goujard C, Chaix ML, Braibant M, **Meyer L** and Barin F on behalf of the ANRS PRIMO Cohort Study Group. Sensitivity to Broadly Neutralizing Antibodies of recently transmitted HIV-1 Clade CRF02\_AG viruses with a focus on evolution over time. ***J Virol*** 2019 ;93 :2 e01492-18
12. Trémeaux P, Lenfant T, Boufassa F, Essat A, Melard A, Gousset M, Delelis O, Goujard C, Rouzioux C, Meyer L**\***, Avettand-Fenoel V\*, for the SEROCO and PRIMO ANRS cohorts. Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection. ***EBioMedicine*** 2019 \* contributed equally

**2018**

1. AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord. [Non-Hodgkin lymphoma risk in adults living with HIV across five continents.](https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/30234606) ***AIDS***. 2018 Nov 28;32(18):2777-86.
2. Alaoui A, Palomino G, Zurawski S, Zurawski G, Coindre S, Dereuddre-Bosquet N, Lecuroux C, Goujard C, Vaslin B, Bourgeois C, Roques P, Le Grand R, Lambotte O, Favier B. Early SIV and HIV infection promotes the LILRB2/MHC-I inhibitory axis in cDCs. ***Cell Mol Life Sci***. 2018 May;75(10):1871-1887.
3. Beloukas A Paraskevis D StasinosK Pantazis N de Mendoza C Bannert N Meyer L Zangerle R Gill J Prins M d’Arminio Montforte A Bakken Kran AM Porter K Touloumi G. HIV-1 Molecular Transmission Clusters in 9 European Countries and Canada: Association with demographic and clinical factors. ***BMC Medicine*** 2018.
4. Beretta M, Moreau A, Bouvin-Pley M, Essat A, Goujard C, Chaix ML, **Meyer L**, Barin F, Martine Braibant on behalf of the ANRS 06 Primo cohort. Properties of env derived from transmitted HIV1 issued from transmission clusters. ***AIDS*** 2018 Sep 10;32(14):1917-1926.
5. Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, **Meyer L**, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. [Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions.](https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/28991888) ***J Acquir Immune Defic Syndr*** 2018 Jan 1;77(1):102-109.
6. Champenois K, Seng R, Persoz A, Essat A, Gaud C, Laureillard D, Robineau O, Duvivier C, Yazdanpanah Y, Goujad C, Meyer L. Calendar trends in sexual behaviours in a cohort of HIV-infected MSM at the era of TasP. *AIDS* **2018** 32(13):1871-9.
7. Coindre S, Tchitchek N, Alaoui L, Vaslin B, Bourgeois C, Goujard C, Avettand-Fenoel V, Lecuroux C, Bruhns P, Le Grand R, Beignon AS, Lambotte O, Favier B. Mass Cytometry Analysis Reveals the Landscape and Dynamics of CD32a + CD4 + T Cells From Early HIV Infection to Effective cART. ***Front Immunol.*** . 2018 Jun 4;9:1217.
8. IeDEA and COHERE Cohort Collaborations. [Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs.](https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/29373672) ***Clin Infect Dis*** 2018;66(6):893-903. doi: 10.1093/cid/cix915.
9. Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. [Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?](https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/28741837) HIV Med. 2018 Jan;19(1):42-48. doi: 10.1111/hiv.12536.
10. Novelli S, Lécuroux C, Avettand-Fenoel V, Seng R, Essat A,Morlat P, Viard JP,Rouzioux C, Meyer L, and Goujard C.Long-term therapeutic impact of the timing of ART in patients diagnosed with primary HIV-1 infection. ***Clin Inf Dis*** 2018; 66(10):1519-1527.
11. Ploquin M, Casrouge A, Madec Y, Noel N, Jacquelin B, Huot N, Duffy D, Jochems S, Micci L, Lécuroux C, Boufassa F, Booiman T, Garcia-Tellez T, Ghislain M, Le Grand R, Lambotte O, Kootstra N, Meyer L, Goujard C, Paiardini M, Albert M, Müller-Trutwin M. DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC+CD4+ cell levels: a surrogate marker candidate of HIV-induced intestinal damage. ***J Int Aids Soc*** 2018,
12. Pressiat C, Hirt D, Treluyer JM, Zheng Y, Morlat P, Naqvi A, Tran L, Viard JP, Avettand-Fenoel V, Rouzioux C, Meyer L, Cheret A; OPTIPRIM Study Group. [Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.](https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/29365125) ***J Antimicrob Chemother.*** 2018 Apr 1;73(4):1020-1024. doi: 10.1093/jac/dkx498
13. Stefic K, Novelli S, Mahjoub N, Seng R, Molina JM, Cheneau C, Barin F, Chaix ML, Meyer L, Delaugerre C and the ANRS PRIMO Study group. Non-reactive HIV-1 Rapid Tests after Sustained Viral Suppression Following Antiretroviral Therapy Initiation During Primary Infection. ***J Inf Dis*** 2018.
14. Wymant C, Blanquart F, Golubchik T, Gall A, Bakker M, Bezemer D, Croucher N, Hall M, Hillebregt M, Ong Swee H, Ratmann O, Albert J, Bannert N, Fellay J, Fransen K, Gourlay A, Grabowski MK, Bartmeyer B, Günthard H, Kivelä P, Kouyos R, Laeyendecker O, Liitsola K, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Cornelissen M, Kellam P, Reiss P, Fraser C. Easy and Accurate Reconstruction of Whole HIV Genomes from Short-Read Sequence Data with SHIVER. ***Virus Evolution*** 2018

**2017**

1. The AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord. Comparison of Kaposi sarcoma risk in HIV-positive adults across five continents: a multiregional multicohort study. ***Clin Inf Dis*** 2017.
2. Alaoui L, Palomino G, Zurawski S, Zurawski G, Coindre S, Dereuddre-Bosquet N, Lecuroux C, Goujard C, Vaslin B, Bourgeois C, Roques P, Le Grand R, Lambotte O, Favier B. Early SIV and HIV infection promotes the LILRB2/MHC-I inhibitory axis in cDCs. ***Cell Mol Life Sci***. 2017 Nov 13. doi: 10.1007/s00018-017-2712-9.
3. Blanquart F, Wymant C, Cornelissen M, Gall A, Bakker M, Bezemer D, Hall M, Hillebregt M, Ong SH, Albert J, Bannert N, Fellay J, Fransen K, Gourlay AJ, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos R, Laeyendecker O, Liitsola K, Meyer L, Porter K, Ristola M, van Sighem A, Vanham G, Berkhout B, Kellam P, Reiss P, Fraser C; BEEHIVE collaboration. Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. ***PLoS Biol***. 2017 Jul 13;15(7):e1002608.
4. Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage GR 3rd, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, Mathews WC, Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice AC, Tate JP, Gill J, Pacheco A, Veloso VG, Bucher HC, Egger M, Furrer H, Porter K, Touloumi G, Crane H, Miro JM, Sterne JA, Costagliola D, Saag M, Hernán MA; HIV-CAUSAL Collaboration; Centers for AIDS Research Network of Integrated Clinical Systems. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. ***Lancet HIV***. 2017 Apr 11. pii: S2352-3018(17)30043-7.
5. Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly prescribed antiretroviral therapy regimens and incidence of AIDS-defining neurological conditions. ***J Acquir Immune Defic Syndr***. 2017 Oct 4.
6. Chaillon A, Essat A, Frange P, Smith DM, Delaugerre C, Barin F, Ghosn J, Pialoux G, Robineau O, Rouzioux C, Goujard C, Meyer L, Chaix ML on behalf the ANRS PRIMO Cohort Study. Spatiotemporal dynamics of HIV-1 transmission in France (1999-2014) and impact of targeted prevention strategies. ***Retrovirology*** 2017. Feb 21;14(1):15.
7. Chereau F, Madec Y, Sabin C, Obel N, Ruiz-Mateos E, Chrysos G, Fidler S, Lehmann C, Zangerle R, Wittkop L, Reiss P, Hamouda O, Estrada Perez V, Leal M, Mocroft A, Garcia De Olalla P, Ammassari A, D'Arminio Monforte A, Mussini C, Segura F, Castagna A, Cavassini M, Grabar S, Morlat P, De Wit S, Lambotte O, Meyer L; HIV Controllers Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCOORD. Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. ***PLoS One***. 2017 Apr 5;12(4):e0173893.
8. Chéret A, Durier C, Mélard A, Ploquin M, Heitzmann J, Lécuroux C, Avettand-Fenoël V, David L, Pialoux G, Chennebault JM, Müller-Trutwin M, Goujard C, Rouzioux C, Meyer L; ANRS OPTIPRIM study group. Impact of early cART on HIV blood and semen compartments at the time of primary infection. ***PLoS One.*** 2017 Jul 14;12(7):e0180191.
9. Ghosn J, Bayan T, Meixenberger K, Tran L, Frange P, d’Arminio Monforte A, Zangerle R, de Mendoza C, Krastinova E, Porter K, Meyer L and Chaix ML on behalf of the CASCADE Collaboration in EuroCoord. CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. ***J Antimicrob Chemother*** 2017 doi:10.1093/jac/dkx247.
10. IeDEA and COHERE Cohort Collaborations. Global trends in CD4 count at start of antiretroviral treatment: collaborative study of treatment programs. ***Clin Inf Dis*** 2017.
11. Lodi S, Costagliola D, Sabin C, Amo JD, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill J, Krentz H, Phillips A, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA. Effect of immediate initiation of antiretroviral treatment in HIV-positive individuals aged 50 years or older. ***J Acquir Immune Defic Syndr***. 2017 Jul 21.
12. Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all? HIV Med. 2017 Jul 25.
13. Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. Timing of cART initiation in Male and Female Migrants Living with HIV in Western Europe: an observational cohort study (1997-2013). ***AIDS***. 2017;31(6):835-46.
14. Novelli S, Lécuroux C, Avettand-Fenoel V, Seng R, Essat A, Morlat P, Viard JP, Rouzioux C, Meyer L, and Goujard C. Long-term therapeutic impact of the timing of ART in patients diagnosed with primary HIV-1 infection. ***Clin Inf Dis*** 2017.
15. Socio-economic Inequalities and HIV Working Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in Euro-Coord. Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe. ***AIDS***. 2017 Jan 14;31(2):253-262.
16. Van Santen DK, Van Der Helm JJ, Del Amo J, Meyer L, D'arminio Monforte A, Price M, Béguelin CA, Zangerle R, Sannes M, Porter K, Bertus Geskus R, Prins M; CASCADE Collaboration in EuroCoord. Lack of decline in Hepatitis C Virus incidence among HIV-positive men who have sex with men during 1990-2014. ***J Hepatol.*** 2017 Apr 12. pii: S0168-8278(17)30209-X.

**2016**

1. Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord. Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies. ***Clin Infect Dis.*** 2016 Nov 15;63(10):1373-1379.
2. Ploquin MJ, Madec Y, Casrouge A, Huot N, Passaes C, Lécuroux C, Essat A, Boufassa F, Jacquelin B, Jochems SP, Petitjean G, Angin M, Gärtner K, Garcia-Tellez T, Noël N, Booiman T, Boeser-Nunnink BD, Roques P, Saez-Cirion A, Vaslin B, Dereudre-Bosquet N, Barré-Sinoussi F, Ghislain M, Rouzioux C, Lambotte O, Albert ML, Goujard C, Kootstra N, Meyer L, Müller-Trutwin MC. Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset. ***PLoS Pathog***. 2016 Aug 10;12(8)
3. Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage GR 3rd, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice AC, Tate JP, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernán MA; Center for AIDS Research Network of Integrated Clinical Systems and the HIV-CAUSAL Collaboration.. When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study. ***J Acquir Immune Defic Syndr***. 2016 Jun 1;72(2):214-21
4. Pantazis N, Touloumi G, Meyer L, Olson A, Costagliola D, Kelleher AD, Lutsar I, Chaix ML, Fisher M, Moreno S, Porter K; CASCADE Collaboration in EuroCoord. The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. ***AIDS***. 2016 Mar 27;30(6):879-88.
5. Borhis G, Burelout C, Chaoul N, Smith N, Goujard C, Meyer L, Paul S, Saoudin H, Hosmalin A, Gilbert C, Herbeuval JP, Richard Y. Plasmacytoid dendritic cells and myeloid cells differently contribute to B-cell-activating factor belonging to the tumor necrosis factor superfamily overexpression during primary HIV infection. ***AIDS***. 2016 Jan 28;30(3):365-76
6. Bouteloup V, Sabin C, Mocroft A, Gras L, Pantazis N, Le Moing V, d’Arminio Monforte A, Mary-Krause M, Roca B, Miro JM, Battegay M, Brockmeyer N, Berenguer J, Morlat P, Obel N, De Wit S, Fätkenheuer G, Zangerle R, Ghosn J, Pérez-Hoyos S, Campbell M, Prins M, Chêne G, Meyer L, Dorrucci M, Torti C, Thiébaut R. The Standard Reference Distribution of CD4 Response to HAART Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. ***HIV Medicine*** 2016
7. [Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.](https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/27535953)
8. Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord. ***Clin Infect Dis.*** 2016 Nov 15;63(10):1373-1379.

**2015**

1. Late presenters working group in COHERE in EuroCoord., Mocroft A, Lundgren J, Antinori A, Monforte Ad, Brännström J, Bonnet F, Brockmeyer N, Casabona J, Castagna A, Costagliola D, De Wit S, Fätkenheuer G, Furrer H, Jadand C, Johnson A, Lazanas M, Leport C, Moreno S, Mussini C, Obel N, Post F, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Loano I, Torti C, Warszawski J, Wittkop L, Zangerle R, Chene G, Raben D, Kirk O. Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. ***Euro Surveill***. 2015;20(47).
2. HIV-CAUSAL Collaboration, Cain LE, Phillips A,Olson A,Sabin C,Jose S,Justice A,Tate J,Logan R,Robins JM,Sterne JA,van Sighem A,Reiss P,Young J,Fehr J,Touloumi G,Paparizos V,Esteve A,Casabona J,Monge S,Moreno S,Seng R,Meyer L,Pérez-Hoyos S,Muga R,Dabis F,Vandenhende MA,Abgrall S,Costagliola D,Hernán MA. Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. ***Clin Inf Dis*** 2015
3. Lodi S, Andrew Phillips, Roger Logan, Ashley Olson, Dominique Costagliola, Sophie Abgrall, Ard van Sighem, Peter Reiss, José M Miró, Elena Ferrer, Amy Justice, Neel Gandhi, Heiner C Bucher, Hansjakob Furrer, Santiago Moreno, Susana Monge, Giota Touloumi, Nikos Pantazis, Jonathan Sterne, Jessica G Young, Laurence Meyer, Rémonie Seng, Francois Dabis, Marie-Anne Vandehende, Santiago Pérez-Hoyos, Inma Jarrín, Sophie Jose, Caroline Sabin, Miguel A Hernán, HIV-CAUSAL Collaboration. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. ***Lancet HIV*** 2015
4. Laanani M\*, Ghosn J\*, Essat A, Melard A, Seng R, Gousset M, Panjo H, Mortier E, Girard PM, Goujard C, Meyer L\*, Rouzioux C\*, for the ANRS PRIMO Cohort Study Group. Impact of the earliness of antiretroviral therapy initiation during primary HIV-1 infection on the decay of cell-associated HIV-DNA. ***Clin Infect Dis*** 2015 Mar 3.
5. Seng R, Goujard C, Krastinova E, Miailhes P, Orr S, Molina JM, Saada M, Piroth L, Rouzioux C and Meyer L, ANRS PRIMO Cohort. Influence of lifelong cumulative HIV viremia on long-term recovery of CD4 cells and the CD4:CD8 ratio among patients on cART. [***AIDS***](http://www.ncbi.nlm.nih.gov/pubmed/?term=Influence+of+lifelong+cumulative+HIV+viremia+on+long-term+recovery+of+CD4+cells+and+the+CD4%3ACD8+ratio+among+patients+on+cART) 2015 Mar 13;29(5):595-607.
6. Krastinova E, Seng R, Lechenadec J, Panjo H, Essat A, Makhloufii D, Obadia M, Bernard L, Goujard C, Meyer L for the ANRS PRIMO Cohort. Does temporary cART during primary HIV infection influence the long-term immunologic and virologic response after cART resumption? ***BMC infectious disease*** 2015 Apr 10;15(1):178.
7. Chéret A, Nembot G, Mélard A, Lascoux C, Slama L, Miailhes P,, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JMM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoen B, Delfraissy JF, Meyer L\* and Rouzioux C\*, for the OPTIPRIM ANRS Study Group. Impact of intensified cART started during Primary HIV-1 infection: results of the OPTIPRIM-ANRS 147 randomised trial. [***Lancet Infect Dis***](http://www.ncbi.nlm.nih.gov/pubmed/?term=Impact+of+intensified+cART+started+during+Primary+HIV-1+infection%3A+results+of+the+OPTIPRIM-ANRS+147+randomised+trial.) 2015 Apr;15(4):387-96.
8. Chéret A\*, Bacchus-Souffan C\*, Avettand-Fenoël V, Mélard A, Nembot G4, Blanc C, Samri A, Saëz-Cirion A, Hocqueloux L, Lascoux-Combe C, Allavena C, Goujard C, Valantin MA, Leplatois A, Meyer L, Rouzioux C\*, and Autran B\* for the OPTIPRIM ANRS-147 Study Group. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. Journal of ***Antimicrobial Chemotherapy*** 2015 Apr 21.
9. Krastinova E, Lecuroux C, Leroy C, Seng R, Cabie A, Rami A, Venet A, Meyer L, Goujard C. Soluble CD14 levels at primary HIV-1 infection predict more rapid disease progression ***J Infect Dis*** 2015 Mar 6.
10. Frange P, Assoumou L, Descamps D, Cheret A, Goujard C, Tran L, Bocket L, Fafi-Kremer S, Guinard J, Morand-Joubert L, Nicot F, Plantier JC, Rogez S, Wirden M, Rouzioux C, Meyer L, Chaix ML, for the French ANRS CO 6 PRIMO Cohort, the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies. ***Journal of Antimicrobial Chemotherapy*** 2015 Feb 6
11. McLaren PJ, Coulonges C, Bartha I, Lenz TL., Deutsch AJ, Bashirova A, Buchbinder S, Carrington MN, Cossarizza A, Dalmau J, De Luca A, Goedert JJ, Gurdasani D, Haas DW, Herbeck JT, Johnson EO, Kirk G, Lambotte O, Luo M, Mallal S, Van Mannen D, Martinez-Picado J, Meyer L, Miro J, Mullins JI, Obel N, Poli G, Sandhu M, Schuitemaker H, Sheamm PR, Theodorou I, Walker BD, Weintrob AC, Winkler CA, Wolinsky SM, Raychaudhuri S, Goldstein D, Telenti A, Paul I. W. de Bakker, Zagury JF, Fellay J. Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. ***PNAS*** 2015

**2014**

1. Bouvin-Pley M, Morgand M, Meyer L, Goujard C, Moreau A, Mouquet H, Nussenzweig M, Pace C, Ho D, Bjorkman P, Baty D, Chames P, Pancera M, Kwong P, Poignard P, Barin F, Braibant M. Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. ***J Virol*** 2014
2. Bouvin-Pley M, Morgand M, Moreau A, Meyer L, Goujard C, Mouquet H, Nussenzweig MC, Pace CS, Ho DD, Bjorkman PJ, Baty D, Chames P, Pancera M, Kwong PD, Poignard P, Barin F, Braibant M. [Adaptation of HIV-1 Envelope Glycoprotein gp120 to Humoral Immunity over the Course of the Epidemic.](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed/25357631) ***AIDS Res Hum Retroviruses***. 2014 Oct; 30 Suppl 1: A224.
3. Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro J, Podzamczer D, Olson A, Arribas J, Moreno S, Meyer L, del Romero J, Dabis F, Bucher H, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, and Hernán M. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurological conditions. ***Neurology*** 2014
4. Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, Monforte AD, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N; The Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Research Europe (COHERE) in EuroCoord. [Long-term mortality in HIV positive individuals virally suppressed for more than three years with incomplete CD4 recovery.](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed/24457342) ***Clin Infect Dis*** 2014.
5. Lecuroux C, Sáez-Cirión A, Girault I, Versmisse P, Boufassa F, Avettand-Fenoël V, Rouzioux C, Meyer L, Pancino G, Lambotte O, Sinet M, Venet A. Both HLA-B\*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers. ***J Virol*** 2014; 88:176-87
6. Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Vanhems P, Boufassa F, Guiguet M, Porter K; CASCADE Collaboration in EuroCoord. [Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection.](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed/24244330) ***PLoS One*** 2013; 14;8(11):e78642.
7. Olson AD, Meyer L, PrinsM, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS and Porter K for CASCADE Collaboration in EuroCoord. An Evaluation of HIV Elite Controller Definitions within a Large Seroconverter Cohort Collaboration. ***PLoS One*** 2014;9(1): e86719
8. Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucci M, Johnson A, Sannes M, Moreno S, Porter K for CASCADE Collaboration in EuroCoord. [Evaluation of rapid progressors in HIV infection as an extreme phenotype.](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed/24872130) ***J Acquir Immune Defic Syndr*** 2014;67:15-21
9. Simonetta F, Hua S, Lécuroux C, Gérard S, Boufassa F, Sáez-Cirión A, Pancino G, Goujard C, Lambotte O, Venet A, Bourgeois C. [High eomesodermin expression among CD57+ CD8+ T cells identifies a CD8+ T cell subset associated with viral control during chronic human immunodeficiency virus infection.](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed/25100841) ***J Virol*** 2014 Oct;88(20):11861-71.
10. Van der Helm J, Geskus R, Lodi S, Meyer L, Schuitemaker H, Gunsenheimer-Bartmeyer B, d’Arminio Monforte A, Olson A, Touloumi G, sabin C, Porter K, Prins M on behalf of Cascade Collaboration in Eurocoord. Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. ***Lancet HIV*** 2014 http://dx.doi.org/10.1016/S2352-3018(14)70016-5.

**2013**

1. Antoni G, Guergnon J, Meaudre C, Samri A, Boufassa F, Goujard C, Lambotte O, Autran B, Rouzioux C, Costagliola D, Theodorou I, Meyer L. MHC-driven HIV-1 control on the long run is not systematically determined at early times post HIV-1 infection. ***AIDS*** 2013;27(11):1707-1716
2. Bouvin-Pley M, Morgand M, Moreau A, Jestin P, Simonnet C, Tran L, Goujard C, Meyer L, Barin F, Braibant M. Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralization over the course of the epidemic. ***PLoS Pathogens*** 2013; 9(7): e1003477
3. Chaix ML, Seng R, Frange P, Tran L, Avettand-Fenoël V, Ghosn J, Reynes J, Yazdanpanah Y, Raffi F, Goujard C, Rouzioux C and Meyer L for the ANRS PRIMO Cohort Study Group. Increasing HIV-1 Non-B Subtype Primary Infections in Patients in France and Effect of HIV Subtypes on Virological and Immunological Responses to cART. ***Clin Inf Dis*** 2013 Mar;56(6):880-7.
4. Chevalier M, Petitjean G, Dunyach-Rémy C, Didier C, Girard PM, Manea ME, Campa P, Meyer L, Rouzioux C, Lavigne JP, Barré-Sinoussi F, Scott-Algara D and Weiss L. The Th17/Treg Ratio, IL-1RA and sCD14 Levels in Primary HIV Infection Predict the TCell Activation Set Point in the Absence of Microbial Translocation. ***PLoS Pathogens*** 2013 ; 9(6) : e1003453
5. Frange P, Meyer L, Ghosn J, Deveau C, Goujard C, Duvivier C, Tubiana R, Rouzioux C, Chaix ML. Prevalence of CXCR4-tropic viruses in clustered transmission chains at the time of primary HIV-1 infection. ***Clinical Microbiology and Infection*** 2013; 19(5): E252-5
6. Frange P, Meyer L, Jung M, Goujard C, Zucman D, Abel S, Hochedez P, Gousset M, Gascuel O, Rouzioux C, Chaix ML; ANRS PRIMO Cohort Study Group. Sexually-transmitted/founder HIV-1 cannot be directly predicted from plasma or PBMC-derived viral quasispecies in the transmitting partner. ***PLoS One*** 2013;9;8(7):e69144.
7. Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combes C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L for the ANRS PRIMO and COPANA cohorts. Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts. ***PLoS One*** 2013; 8(8): e71473
8. [Ladell K](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Ladell%20K%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Hashimoto M](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Hashimoto%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Iglesias MC](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Iglesias%20MC%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Wilmann PG](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Wilmann%20PG%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [McLaren JE](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=McLaren%20JE%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Gras S](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Gras%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Chikata T](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Chikata%20T%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Kuse N](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Kuse%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Fastenackels S](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Fastenackels%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Gostick E](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Gostick%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Bridgeman JS](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Bridgeman%20JS%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Venturi V](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Venturi%20V%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Arkoub ZA](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Arkoub%20ZA%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Agut H](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Agut%20H%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [van Bockel DJ](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=van%20Bockel%20DJ%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Almeida JR](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Almeida%20JR%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Douek DC](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Douek%20DC%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Meyer L](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Meyer%20L%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Venet A](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Venet%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Takiguchi M](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Takiguchi%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Rossjohn J](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Rossjohn%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Price DA](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Price%20DA%5BAuthor%5D&cauthor=true&cauthor_uid=23521884), [Appay V](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed?term=Appay%20V%5BAuthor%5D&cauthor=true&cauthor_uid=23521884). A molecular basis for the control of pre-immune escape variants by HIV-specific CD8+ T-cells. [***Immunity***.](http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed/23521884) 2013;38(3):425-36
9. Lecuroux C, Sáez-Cirión A, Girault I, Versmisse P, Boufassa F, Avettand-Fenoël V, Rouzioux C, Meyer L, Pancino G, Lambotte O, Sinet M, Venet A. Both HLA-B\*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers. ***Journal of Virology*** 2013
10. Ledergerber B, Costagliola D, Lodwick R, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, Günthard HF, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Chrysos G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Predictors of CD4 cell counts of HIV-1 - infected persons after virologic failure to all three original antiretroviral drug classes. ***J Infect Dis*** 2013
11. McLaren PJ, Coulonges C, Ripke S, van den Berg L, Buchbinder S, Carrington M, Andrea Cossarizza A, Dalmau J, Deeks SG, Delaneau O, De Luca A, Goedert JJ, Haas D, Herbeck JT, Kathiresan S, Kirk GD, Lambotte O, Luo M, Mallal S, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, O'Brien SJ, Pereyra F, Plummer FA, Poli G, Qi Y, Sandhu MS, Shea P, Schuitemaker H, Theodorou I, Vannberg F, Veldink J, Walker BD, Weintrob A, Winkler CA, Wolinsky S, Telenti A, Goldstein DB, de Bakker PIW, Zagury JF, Fellay J on behalf of the International Collaboration for the Genomics of HIV. Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls. ***PLoS Pathogens*** 2013;9:e1003515
12. Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d’Arminio Monforte MD, Amornkul P, Bartmeyer B, Sannes M, Venet A, Lambotte O and Meyer L on behalf of the CASCADE Collaboration in Eurocoord. Natural History of HIV control since seroconversion: experience from CASCADE. ***AIDS*** 2013
13. Meyer L, Seng R, Allègre T, Timsit J, Talamali A, Reynes J, Goujard C. Increasing frequency of self-reported orogenital HIV-1 transmission among men having sex with men: the ANRS PRIMO Cohort. ***J Acquir Immune Defic Syndr*** 2013; 63:e164-6.
14. The Pursuing Later Treatment Option II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group. Predictors of CD4 cell counts of HIV-1-infected persons after virologic failure to all three original antiretroviral drug classes. ***J Infect Dis*** 2013. Mar 1;207(5):759-67
15. Porter K, Lodi S, Meyer L. [Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion--reply.](http://www.ncbi.nlm.nih.gov/pubmed/23529555) ***JAMA Intern Med*** 2013;173(6):476-7.
16. Sáez-Cirión A, Hocqueloux L, Girault I, Avettand-Fenoel V, Versmisse P, Melard A, Guergnon J, Goujard C, Viard JP, Boufassa F, Lambotte O, Prazuck T, Meyer L, Venet A, Pancino G and Rouzioux C for the ANRS VISCONTI Study Group. HIV-1 infected patients in remission after interruption of prolonged antiretroviral therapy initiated during primary infection. ***PLoS*** ***Pathogens*** 2013;9(3):e1003211
17. Touloumi G, Pantazis N, Chaix ML, Bucher HC, Zangerle R, Bakken Kran AM, Thiebaut R, Masquelier B, Kucherer C, d’Arminio Monforte A, Meyer L, Porter K for CASCADE Collaboration in EuroCoord. Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE Collaboration. ***PLoS*** ***One*** 2013.
18. Van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chêne G, Dorrucci M, Muga R, Porter K, Prins M; CASCADE Collaboration in EuroCoord. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. ***Gastroenterology***. 2013;144(4):751-760

**2012**

1. Costagliola D, Lodwick R, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Amanda Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez‑Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Trends over calendar time in virological and clinical outcomes in individuals with HIV-1 infection and virologic failure of drugs from three antiretroviral drug classes: a cohort study. ***Lancet*** ***Infect*** ***Dis*** 2012; 12:119-27.
2. Dutertre C, Amraoui S, DeRosa A, Jourdain JP, Vimeux L, Goguet M, Degrelle S, Feuillet V, Liovat AS, Müller-Trütwin M, Decroix N, Deveau C, Meyer L, Goujard C, Loulergues P, Launay O, Richard Y, Hosmalin A. Pivotal role of M-DC8+ monocytes from viremic HIV-infected patients in TNF over-production in response to microbial products. ***Blood*** 2012;120(11):2259-68
3. Frange P, Meyer L, Deveau C, Tran L, Goujard C, Ghosn J, Girard PM, Morlat P, Rouzioux C, Chaix ML and the French ANRS CO6 PRIMO Cohort Study Group. Primary HIV-1 Infection Contributes to the Spread of the Viral Epidemic throughout the whole French Territory with a Recent Increasing Frequency. ***PLoS*** ***One*** 2012; 7(2):e31695
4. Ghosn J, Persoz A, Zitoun Y, Chaix ML, Amri I, Reynes J, Raffi F, Deveau C, Meyer L, Goujard C. Thrombocytopenia during primary HIV-1 infection predicts the risk of recurrence during chronic infection. ***JAIDS*** 2012;60:e112-4.
5. Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A Delfraissy JF, Venet A, Meyer L, Sinet M and the ANRS CO6 PRIMO Study Group. HIV-1 control after interruption of antiretroviral treatment initiated during primary infection: importance of early patient characteristics and impact of therapy. ***Antiviral*** ***Ther*** 2012;17(6):1001-9
6. Guergnon J, Dalmasso C, Broet P, Meyer L, Westrop SJ, Imami N, Vicenzi E, Morsica G, Tinelli M, Zanone Poma B, Goujard C, Potard V, Gotch FM, Casoli C, Cossarizza A, Macciardi F, Debré P, Delfraissy JF, Galli M, Autran B, Costagliola D, Poli G, Theodorou I, Riva A and the GISHEAL group. Both class-I and class-III MHC genetic subregions contribute to natural long-term non progression in HIV infection. ***J*** ***Inf*** ***Dis*** 2012;205(5):718-24.
7. HIV Causal Group. Impact of Immune Reconstitution Inflammatory Syndrome on the effect of antiretroviral therapy on tuberculosis incidence: a prospective study of HIV-positive individuals in high income countries. ***Clin*** ***Inf Dis*** 2012; 54:1364-72.
8. Jarrin I, Pantazis N, Gill MJ, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G; Johnson A, Hamouda O, Garcia de Olalla P, Porter K, Del Amo J. Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in sercoconverters in Europe, Canada, and Australia. ***Clin*** ***Inf*** ***Dis*** 2012;54:111-8.
9. Leruez-Ville M, Seng R, Morand P, Boufassa F, Boue F, Deveau C, Rouzioux C, Goujard C, Seigneurin JM, Meyer L. High blood EBV load is a predictor of progression to AIDS related systemic B lymphoma. ***HIV Medicine*** 2012; 13(8):479-87
10. Liovat AS, Rey-Cuille MA, Lecuroux C, Jacquelin B, Girault I, Lebon P, Petitjean G, Zitoun Y, Venet A, Barré-Sinoussi F, lebon P, Meyer L, Sinet M, Muller-Trutwin MC, and the ANRS PRIMO Study Group. Acute pro- and anti-inflammatory plasma biomarkers of T cell activation setpoint levels and disease progression in HIV-1 infection. ***PLoS One*** 2012; 7(10):e46143
11. Lodi S, Meyer L, Kelleher A, Rosinska M, Ghosn J, Sannes M, Porter K for the CASCADE collaboration in EuroCoord. Immuno-virological control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. ***Arch Int Med*** 2012;172(16):1252-5
12. Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A, Jansen K, Masquelier B, García F, De Wit S, Stephan C, Niels Obel N, Fätkenheuer G, Castagna A, Sambatakou H, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug experienced people with HIV in Europe. ***J*** ***Acquir*** ***Immune*** ***Defic*** ***Syndr*** 2012; 59(3):294-9.
13. Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G on behalf of CASCADE Collaboration and ANRS 1220 Primo-CI Study Group. Differences in HIV disease progression in the absence of antiretroviral therapy between European and African seroconverters in Europe and in sub-Saharan Africa. ***PloS*** ***One*** 2012;7(3):e32369.
14. Petitjean G, Chevalier MF, Tibaoui F, Didier C, Manea ME, Liovat AS, Campa P, Müller-Trutwin M, Girard PM, Meyer L, Barré-Sinoussi F, Scott-Algara D, Weiss L. Level of double negative T cells, which produce TGF-a and IL-10, predicts CD8 T-cell activation in primary HIV-1 infection. ***AIDS*** 2012;26:139-48.
15. Rachas A, Warszawski J, Le Chenadec J, Legeai C, Teglas JP, Goujard C, Rouzioux C, Mandelbrot L, Tubiana R, Meyer L. Does Pregnancy Affect the Early Response to cART? ***AIDS*** 2012; 27(3):357-67
16. Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, Obel, N, Kirk O, Miro JM, Furrer HJ, Castagna A, De Wit S, Munoz J, Kjaer J, Colin C, Grarup J, Chene G, Bucher H and The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. [CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE.](http://www.ncbi.nlm.nih.gov/pubmed/22448150) ***PLoS Med*** 2012; 9(3):e1001194.

**2011**

1. Ghosn J, Galimand J, Raymond S, Meyer L, Deveau C, Goujard C, Izopet J, Rouzioux C and Chaix ML. X4 Tropic Multi-drug Resistant Quasi-species Detected at the Time of Primary HIV-1 Infection (PHI) Remain Exclusive or at Least Dominant Far from PHI (ANRS PRIMO Cohort CO 06). ***PLoS*** ***One*** 2011; 6(8): e23301. Epub 2011
2. The HIV-CAUSAL Collaboration. When to Initiate Combined Antiretroviral Therapy to ReduceMortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries: An Observational Study. ***Ann*** ***Int*** ***Med*** 2011; 154:509-515
3. Leoz M, Chaix ML, Delaugerre C, Rivoisy C, Meyer L, Rouzioux C, Simon F, Plantier JC. [Circulation of multiple patterns of unique recombinant forms B/CRF02\_AG in France: precursor signs of the emergence of an upcoming CRF B/02.](http://www.ncbi.nlm.nih.gov/pubmed/21522007) ***AIDS***. 2011;25:1371-7.
4. Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, del Amo J, Johnson A, Babiker A, Porter K on behalf of the CASCADE Collaboration in EuroCoord. Time from HIV Seroconversion to Reaching CD4 Thresholds <200, <350 and <500 Cells/mm3; Assessment of Need following Changes in Treatment Guidelines. ***Clin*** ***Inf*** ***Dis*** 2011; 53(8):817-825.
5. Seng R, Rolland M, Beck-Wirth G, Souala F, Deveau C, Delfraissy JF, Goujard C, Meyer L. Trends in unsafe sex and influence of viral load among patients followed since primary HIV infection, 2000 to 2009. ***AIDS*** 2011;25:977-88.

**2010**

1. Frange P, Chaix ML, Raymond S, Galimand J, Deveau C, Meyer L, Goujard C, Rouzioux C, Izopet J; the French ANRS CO 06 PRIMO Cohort study group. Low frequency of CXCR4-using viruses in patients at the time of primary HIV-1 non-B infection. ***J*** ***ClinMicrobiol*** 2010
2. Galimand J, Frange P, Rouzioux C, Deveau C, Avettand-Fenoël V, Ghosn J, Lascoux C, Goujard C, Meyer Land Chaix ML. Evidence of HIV-1complex and second-generation recombinant strains among patients infected in1997-2007 in France: ANRS CO06 PRIMO Cohort. ***AIDS Research and Human Retroviruses*** 2010;
3. Ghosn J, Galimand J, Meyer L, Descamps D, Vabret A, Deveau C, Yeni P, Goujard C, Rouzioux C, Chaix ML for the French ANRS CO06 PRIMO Cohort. Undetectable HIV-1 RNA Load With the COBASTaqMan v1.0 in a Patient Diagnosed at the Time of Primary HIV-1 Infection. ***J Med Virol*** 2010 ;82:1816–1818.
4. Ghosn J, Deveau C, Chaix ML, Goujard C, Galimand J, Zitoun Y, Allegre T, DelfraissyJF, Meyer L, Rouzioux C. Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort. ***Journal*** ***of*** ***Antimicrobial*** ***Chemotherapy*** 2010; 65:741-8.
5. HIV Causal Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. ***AIDS*** 2010 ; 24 :123-37
6. Le Vu S, Le Strat Y, barin F, Pillonel J, Cazein F, Bousquet V, Brunet S, Thierry D, Semaille C, Meyer L, Desenclos JC. Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. ***Lancet Inf Dis*** 2010;
7. Louis S, Fery L, Henno L, Vimeux L, Diocou S, Kahi S, Deveau C, Meyer L, Goujard C and Hosmalin A. IL-23 and IL-12p70 production by monocytes and dendritic cells in primary HIV-1 infection. ***Journal*** ***of*** ***Leukocyte*** ***Biology*** 2010;
8. Sommen C, Commenges D, Le Vu S, Meyer L, Alioum A. Estimation of the distribution of infection times using longitudinal serological markers of HIV: implications for the estimation of HIV incidence. ***Biometrics2010***

**2009**

1. Troude P, Chaix ML, Tran L, Deveau C, Seng R, DelfraissyJF, Rouzioux C, Goujard C, Meyer L. No evidence of a change in HIV-1 virulence since 1996 inFrance; a study based on the CD4 cell count and HIV RNA/DNA levels at primary infection. ***AIDS*** 2009; 23:1261-7.
2. Lécuroux C, Girault I, Urrutia A, DoisneJM, Deveau C, Goujard C, Meyer L, Sinet M and Venet A. Identification of a particular HIV-specific CD8+ T cell subset with aCD27+ CD45RO-/RA+ phenotype and memory characteristics after initiation of HAART during acute primary HIV infection. ***Blood*** 2009 113(14):3209-17.
3. Lécuroux C, Girault I, Urrutia A, Goujard C, Deveau C, Meyer L, Lambotte O, Chaix ML, Boutboul F, Autran B, Sinet M, Venet A, and the ANRS PRIMO Cohort, ALT Cohort and the ANRS and EP36-HIC Study Group. HAART Initiation During Primary HIV Infection Enhances Both CD127 Expression and the Proliferative Capacity of HIV-Specific CD8+ T Cells. ***AIDS*** 2009 23(13):1649-58.
4. Chaix ML, Diane Descamps D, WirdenW, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Christine Rouzioux C, Meyer L, Costagliola D and the ANRS AC11 Resistance Group, Cohort PRIMO ANRS CO 06 and FHDHANRS CO4 Study Groups. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 inFrance. ***AIDS*** 2009; 23:717-24
5. Frange P, Galimand J, Goujard C, Deveau C, Ghosn J, Rouzioux C, Meyer L, Chaix ML. High frequency of X4/DM tropic viruses in PBMC samples from patients with Primary HIV-1 Subtype B Infection in 1996-2007: the French ANRS Primo Cohort Study. ***J*** ***Antimicrob*** ***Chemotherapy*** 2009 64(1):135-41
6. Goujard C, Chaix ML, Lambotte O, Deveau C, Sinet M, Théodorou I, Courgnaud V, Rouzioux C, DelfraissyJF, Venet A, Meyer L and the ANRS PRIMO Study Group. Spontaneous control of viral replication in primary HIV infection: how is "HIV controller" status established? ***ClinInf*** ***Dis*** 2009; 49(6):982-6
7. Collaboration of Observational HIV Epidemiological Research in Europe study group. Prognosis of HIV-associated non-Hodkin lymphoma in patients starting combination antiretroviral therapy. ***AIDS*** 2009;23:2029-37.

**2008**

1. Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, Chaix ML, Lambotte O, AvettandFenoel V, Le Clerc S, Denis de Senneville L, Deveau C, Boufassa F, Debré P, DelfraissyJF, Broet P, Theodorou I. Distinct Genetic Loci Control Plasma HIV-RNA and Cellular HIV-DNA Levels in HIV-1 Infection: the ANRS Genome Wide Association 01 Study. ***PLoS*** ***ONE*** 2008 ;3(12):e3907
2. Seng R, Goujard C, Desquilbet L, Sinet M, Rouzioux C, Deveau C, Boufassa F, DelfraissyJF, Meyer L, Venet A. Rapid CD4+ cell decrease after transient cART initiated during Primary HIV infection (ANRS PRIMO and SEROCO cohorts). ***J Acquir*** ***Immune*** ***DeficSyndr*** 2008 2008; 49:251-8.
3. Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) Study Group. Response to combination antiretroviral therapy: variation by age. ***AIDS*** 2008;22:1463-73.
4. Frange P, Galimand J, Vidal N, Goujard C, Deveau C, Souala F, Peeters M, Meyer L, Rouzioux C and Chaix ML. New and Old Complex Recombinant HIV-1 Strains Entering in France among Patients with Primary Infection in 1996-2006: the French ANRS CO06 Primo Cohort Study. ***Retrovirology*** 2008;5(1):e-pub
5. Vidal N, Frange P, Chaix ML, Mulanga C, Lépira F, EdidiBazepeo S, Goujard C, Meyer L, Rouzioux C, Delaporte E, Peeters M. Characterisation of an old complex circulating recombinant form, CRF27\_cpx, originating from the Democratic Republic of Congo (DRC) and circulating in France. ***Aids*** ***Res*** ***Hum*** ***Retrov*** 2008; 24:315-21.

**2007**

1. Chaix ML, Desquilbet L, Descamps D, Costagliola D, Deveau C, Galimand J, Goujard C, Signori-Schmück A, Schneider V, Tamalet C, Pellegrin I, Wirden M, Masquelier B, Brun-Vezinet F, Rouzioux C, Meyer L. Suboptimal virological response to HAART in patients infected with HIV-1 resistant strains and treated at the time of primary infection: The French ANRS Resistance Network Survey. ***Antiviral*** ***Therapy*** 2007; 12 :1305-10.
2. Courgnaud V, Seng R, Becquart P, Boulahtouf A, Rouzioux C, Boufassa F, Deveau C, Van de Perre P, Meyer L, Foulongne V. HIV-1 coinfection prevalence in two cohorts of early seroconverters in France. ***AIDS*** 2007; 21:1055-6.

**2006**

1. [Adalid-Peralta L, Grangeot-Keros L, Rudent A, Ngo-Giang-Huong N, Krzysiek R, Goujard C, Deveau C, Le Gall M,](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17105510&ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) Meyer L, [Emilie D, Rouzioux C.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17105510&ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection. ***HIV*** ***Med*** 2006;7:514-9.
2. Van de Vijver D, WensingAMJ, Angarano G, Åsjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, SchmitJC, Schneider F, Schuurman R, Soriano, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M and Boucher CAB on behalf of the SPREAD Programme. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes***. J*** ***Acquir*** ***Immune*** ***DeficSyndr*** 2006; 41: 352-60.
3. Lievre L, Deveau C, Gerbe J, Enel P, Tran L, De Castro N, Costagliola D, Meyer L, the Primo Study Group and the Clinical Epidemiology Group of the French Hospital Database on HIV. Yearly number of patients diagnosed with primary HIV-1 infection in France estimated by a capture-recapture approach. ***AIDS*** 2006 (20(18):2392-5).
4. Ghosn J, Deveau C, Goujard C, Garrigue I, Saïchi N, Galimand J, Nagy Z, Rouzioux C, Meyer L, and Chaix ML for the French PRIMO Cohort Study Group. Increase in HCV incidence in HIV-1 infected patients followed since primary-infection. ***SexTransmInf*** 2006 (82(6):458-60).
5. Goujard C et al. Primo-infection par le VIH. In Prise en charge des personnes infectées par le VIH. Recommandations du groupe d’experts. Rapport 2006, sous la direction du Pr P. Yéni. Médecine-Sciences. Flammarion. Paris.
6. Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, Deveau C, Sinet M, Galimand J, DelfraissyJF, Venet A, Rouzioux C, Morlat P and the ANRS PRIMO study group. The CD4 Cell Count and HIV DNA level are independent predictors of progression after Primary HIV-1 infection in untreated patients. ***ClinInf*** ***Dis*** 2006;42:709-15.
7. Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, Galimand J, Harzic M, Tamalet C, Meyer L, Rouzioux C, Chaix ML. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. ***AIDS*** 2006;20:159-70.

**2005**

1. Desquilbet L, Meyer L. Variables dépendantes du temps dans le modèle de Cox. Théorie et pratique avec le logiciel SAS® (version 8.2). ***RevEpidemiol*** ***Santé*** ***Publ*** 2005; 53:51-68.
2. Descamps D, Chaix ML, André P, Brodard V, Cottalorda J, Deveau C, Harzic M, Ingrand D, Izopet J, Kohli E, Masquelier B, Mouajjah S, Palmer P, Pellegrin I, Plantier JC, Poggi C, Rogez S, Ruffault A, Schneider V, Signori-Scmück A, Tamalet C, Wirden M, Rouzioux C, Brun-Vézinet F, Meyer L, Costagliola D. French national sentinelsurvey of antiretroviraldrugresistance in patients with HIV-1 primary infection and in antiretroviral-naïve chronicallyinfected patients in 2001-2002. ***J*** ***Acquir*** ***Immune*** ***DeficSyndr*** 2005; 38:545-52.
3. WensingAMJ, van de Vijver DA, Angarano G, Åsjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola C, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M and Boucher CA on behalf of the SPREAD Programme. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. ***J*** ***Inf*** ***Dis*** 2005 ; 192 :958-66.
4. Dray-SpiraRM, Gueguen A, Persoz A, Deveau C, Lert F, DelfraissyJF, Meyer L and the PRIMO study group. Temporary employment, absence of stable partnership and risk of hospitalisation or death during the course of HIV infection. ***J*** ***Acquir*** ***Immune*** ***DeficSyndr*** 2005;40:190-7.
5. Dray SpiraRM, Persoz A, Boufassa F, Gueguen A, Goujard C, Lert F, Allegre T, Meyer L and the PRIMO Cohort Study Group. Employment loss following HIV infection in the era of highly active antiretroviral therapies. ***Eur J Public Health*** 2005 ;16:89-95.
6. Barin F, Meyer L, Lancar R, Deveau, Gharib M, Laporte A, DesenclosJC, Costagliola D. A new immunoassay for the identification of recent HIV-1 infections: development, validation and use on dried blood spots. ***J ClinMicrobiol*** 2005; 43: 4441-7.
7. Kamga I, Kahi S, Develioglu L, Lichtner M, Marañón C, Deveau C, Meyer L, Goujard C, Lebon P, Sinet M and Hosmalin A. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. ***J Inf Dis*** 2005 ;192 :303-10.

**2004**

1. Lacabaratz-Porret C, Viard JP, Goujard C, Lévy Y, Rodallec A, Deveau C, Venet A, Sinet M. Presence of HIV-specific CD4+ T cell responses in HIV-infected subjects with sustained virological control following HAART. ***J Acquir*** ***Immune*** ***Defic*** 2004; 36 :594-9.
2. Anfossi N, DoisneJM, Peyrat MA, Ugolini S, Bonnaud O, Bossy D, Pitard V, Merville P, Moreau JF, DelfraissyJF, Dechanet-Merville J, Bonneville M, Venet A, Vivier E. Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells. ***J*** ***Immunol*** 2004, 173:7223-7229.
3. Goujard C et al. Primo-infection par le VIH. In Prise en charge des personnes infectées par le VIH. Recommandations du groupe d’experts. Rapport 2004, sous la direction du Pr JF. Delfraissy. Médecine-Sciences. Flammarion. Paris.
4. Desquilbet L, Goujard C, Rouzioux C, Sinet M, Deveau C, Chaix ML, Séréni D, Boufassa F, DelfraissyJF and Meyer L for the PRIMO and SEROCOstudy groups. Does transient HAART during primary infection lower the virological set-point? ***AIDS*** 2004; 18:2361-9.
5. Schiffer V, Deveau C, Meyer L, Iraqui I, Nguyen-Martel A, Chaix ML, DelfraissyJF, Rouzioux C, Venet A and Goujard C for the French PRIMO Cohort Study group. Recent changes in the management of primary HIV-1 infection: results from the French Primo cohort. ***HIV Medicine*** 2004; 5:326-33.
6. Pacanowski J, Develioglu L, Kamga I, Sinet M, Desvarieux M, Girard PM, Hosmalin A. Early plasmacytoid dendritic cell changes predict plasma HIV rebound un primary infection. ***J Inf*** ***Dis*** 2004;190:1889-92.
7. DoisneJM, Urrutia A, Lacabaratz C, Goujard C, Meyer L, Chaix ML, Sinet M, Venet A. CD8+ T cells specific for EBV, CMV and influenza virus are activated during primary HIV infection. ***J Immunol*** 2004; 173: 2410-8.

**2003**

1. Chaix ML, Descamps D, Harzic M, Schneider V, Deveau C, Tamalet C, Pellegrin I, Izopet J, Ruffault A, Masquelier B, Meyer L, Rouzioux C, Brun-Vezinet F, Costagliola D, the PRIMO Cohort Study, the PRIMOFERON Study, the PRIMSTOP study and the ANRS Antiretroviral Resistance Study Group. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with HIV-1 primary infection in France. ***AIDS*** 2003; 17: 2635-43.
2. Lacabaratz-Porret C, Urrutia A, DoisneJM, Goujard C, Deveau C, Dalod M, Meyer L, Rouzioux C, DelfraissyJF, Venet A, Sinet M. Impact of antiretroviral therapy and changes in viral load on HIV-specific T cell responses in primary HIV infection. ***J Inf Dis*** 2003; 187: 748-57.

**2002**

1. Desquilbet L, Deveau C, Goujard C, Hubert JB, Derouineau J, Meyer L and the PRIMO Study group. Increase in at-risk sexual behaviour among HIV-1-infected patients followed in the French PRIMO cohort. ***AIDS*** 2002; 16:2329-33.
2. Harzic M, Pellegrin I, Deveau C, Chaix ML, Garrigue I, Dubeaux B, Ngo N, Rouzioux C, Goujard C, Hoen B, Sereni D, DelfraissyJF, Meyer L and the PRIMO Study Group. Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): Frequency and response to treatment. ***AIDS*** 2002 16:793-6.

**2001**

1. Pacanowski J, Kahi S, Baillet M, Lebon P, Deveau C, Goujard C, Meyer L, Oksenhendler E, Sinet M, Hosmalin A. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. ***Blood*** 2001; 98:3016-21.
2. Ngo-Giang-Huong N, Deveau C, Da Silva I, Pellegrin I, Venet A, Harzic M, Sinet M, DelfraissyJF, Meyer L, Goujard C, Rouzioux C. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of HAART. ***AIDS*** 2001; 15:665-73.
3. Goujard C, Boufassa F, Deveau C, Laskri D, Meyer L for the PRIMO group. Incidence of clinical lipodystrophy in HIV-1 infected patients treated during primary infection. ***AIDS*** 2001; 15:282-4.

**1999**

1. Dalod M, Dupuis M, DescheminJC, Goujard C, Deveau C, Meyer L, Ngo N, Rouzioux C, Guillet JG, DelfraissyJF, Sinet M, Venet A and PRIMO Study group. Weak anti-HIV CD8+ T-cell effector activity in HIV primary infection. ***J*** ***Clin Invest***1999; 104:1431-9.
2. Meyer L, Goujard C. La primo-infection VIH. ***La*** ***Revue*** ***du*** ***Praticien*** 1999; 49:1750-6.